Therapy comparison for multiple sclerosis

Long-term effect of a newly developed drug compared with teriflunomide.

At a glance

Project leader : Dr. Anna Drewek
Deputy of project leader : Dr. Christoph Hofer
Project status : completed
Funding partner : Third party

Description

In this project, the longterm effectiveness (i.e. EDSS progression) of a only clinically tested new drug was compared to Teriflunomide. For this purpose, in a first step, the two data sets (Randomized Clinical Trial Data of the new drug and observational Data for Teriflunomide) were processed for comparability using statistical tools such as Propensity Score Matching. For the effectiveness, Cox regression and various sensitivity analyses were applied.

Publications

Braune, Stefan; Drewek, Anna; Bergmann, Arnfin; Keenan, Alex; Gandhi, Kavita; Schuler, Maximilian; van Denderen, Jacqueline; Ait-Tihyaty, Maria; H Le, Hoa,

2022.

Assessing the impact of persistency for disease-modifying therapies in a German registry for multiple sclerosis [poster].

In:

38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Amsterdam, The Netherlands, 26-28 October 2022.
Braune, Stefan; Drewek, Anna; Bergmann, Arnfin; Schuler, Maximilian; Ait-Tihyaty, Maria; H Le, Hoa; Keenan, Alex; Gandhi, Kavita; van Denderen, Jacqueline,

2022.

Is there an impact of early initiation of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis in the German registry? [poster].

In:

38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Amsterdam, The Netherlands, 26-28 Oktober 2022.

go back